← Leaderboards
George V Aslanidi
University Of Minnesota
$2,567,167
Attributed
$4,697,083
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $925.4K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,897,083 · 3
FDA$1,800,000 · 1
By mechanism
R01$4,259,833 · 3
R21$437,250 · 1
Top collaborators
- Christina A. Pacak3 shared
- Arun Srivastava3 shared
- Antonella M Borgatti2 shared
- Chen Ling2 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Antonella M Borgatti$1,234,695
- Bruce R. Blazar$144,460,093
Others in their field
Other Emerging Leaders on “Next Generation”
- Ted Ross · University Of Georgia$71,962,304
- Laura Ferrarese · Association Of Universities For Research In Astronomy, Inc.$47,742,424
- Julie Brisset · The University Of Central Florida Board Of Trustees$41,275,036
- Scott Dahm · Association Of Universities For Research In Astronomy, Inc.$39,961,632
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- John E West · University Of Texas At Austin$34,399,667
Research focus
Next GenerationSafetyDependovirusImmune ResponseCd8-Positive T-LymphocytesPublic HealthVectorAdeno-Associated Viral VectorDesignSerotypingTransduction EfficiencyTraffickingResponseGenesEngineeringThreonineSerineBiomedical EngineeringDna CassetteMolecularDoseCapsidInflammatory ResponseSurface
Grant awards (11)
Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma.$488,155
R01 · FY2025 · CA · contact PI
Mingling life imaging and cell subpopulations expression analysis in NHP lungs targeted with exosome associated double AAV vectors$437,250
R21 · FY2025 · AI · contact PI
Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma.$503,863
R01 · FY2024 · CA · contact PI
Optimized Production and Validation of Rationally Designed AAV Vectors for Cockayne Syndrome Gene Therapy$600,000
R01 · FY2023 · FD · contact PI
Optimized Production and Validation of Rationally Designed AAV Vectors for Cockayne Syndrome Gene Therapy$600,000
R01 · FY2022 · FD · contact PI
Optimized Production and Validation of Rationally Designed AAV Vectors for Cockayne Syndrome Gene Therapy$600,000
R01 · FY2021 · FD · contact PI
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors$293,563
R01 · FY2021 · GM
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors$293,563
R01 · FY2020 · GM
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors$293,563
R01 · FY2019 · GM
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors$293,563
R01 · FY2018 · GM
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors$293,563
R01 · FY2017 · GM